News for DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the e

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsRick Pauls - President, Chief...

DiaMedica Therapeutics announced Q3 financial results, with total cash of $50.2 million and working capital of $46.5 million.

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Aug 08, 2024 / 12:00PM GMTOperator Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics second quarter 2024 conference Call. An audio rec

DiaMedica Therapeutics Inc. (NASDAQ:NASDAQ:DMAC) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ETCompany ParticipantsRick Pauls - President, Chief...

Here is how DiaMedica Therapeutics, Inc. (DMAC) and Elutia Inc. (ELUT) have performed compared to their sector so far this year.

The surge in demand for intracranial stents is predominantly driven by the growing occurrence of neurological conditions like intracranial stenosis and...

An interim futility analysis by DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1’25. Read more on DMAC stock here.

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

Earnings call: DiaMedica reports on ReMEDy2 trial progress and finances

Omega Advisors portfolio, holdings, 13F and news. Updated: 2023-08-30

Omega Advisors portfolio, holdings, 13F and news. Updated: 2022-03-28

Gainers Red Cat Holdings, Inc. (NASDAQ:RCAT) shares surged 50% to close at $3.60 on Monday after the company said its subsidiary, Skypersonic, I...

Midway through trading Monday, the Dow traded up 0.70% to 35,041.74 while the NASDAQ fell 0.51% to 14,970.85. The S&P also rose, gaining 0.02%...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au...

During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group Holding (NYSE:BABA) was the ...

Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week ...